VentriPoint Diagnostics Ltd (TSE:VPT)
:VPT
Want to see TSE:VPT full AI Analyst Report?
VPT Stock Chart & Stats
C$0.12
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.12
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.19
Previous CloseN/A
Volume32.00K
Average Volume (3M)106.78K
Market Cap
C$23.11M
Enterprise ValueC$26.00M
Total Cash (Recent Filing)C$55.39K
Total Debt (Recent Filing)C$2.60M
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding192,577,940
10 Day Avg. Volume85,718
30 Day Avg. Volume106,775
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-5.63
Price to Sales (P/S)128.71
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue AccelerationSustained, large top-line growth reflects successful commercial traction and expanding customer adoption of the company’s device offering. Over a 2–6 month horizon this durable revenue momentum improves scale economics potential and supports further investment in commercialization.
Improved Gross MarginsA materially higher gross margin indicates favorable product economics and pricing power typical of differentiated medical-device offerings. If sustained, this margin profile creates a durable path to profitability as fixed costs are leveraged with continued revenue growth.
Improving Cash Burn TrendA meaningful reduction in operating cash outflows signals management progress on expense control or more efficient revenue conversion. While still negative, this durable improvement reduces near-term financing pressure and lengthens runway if the trend continues over coming quarters.
Bears Say
Deeply Negative Equity And Rising LeverageNegative equity and escalating debt materially weaken financial flexibility and increase refinancing and dilution risk. Over 2–6 months this constrained capital structure limits funding options, raises borrowing costs, and can force dilutive capital raises that impair long-term shareholder value.
Persistent Cash Burn; Worsening Free Cash FlowConsistent negative operating cash flow and a sharply worse free cash flow trend show losses are translating into real cash outflows. This structural cash deficit requires ongoing external financing and elevates execution risk, constraining investments and strategic optionality.
Large Operating Losses; No Operating Leverage YetRevenue growth has not produced operating leverage; large recurring operating losses indicate SG&A and R&D scale faster than sales. Persisting at this level would impair prospects for sustainable profitability and limit the company's ability to self-fund growth over the medium term.
VPT FAQ
What was VentriPoint Diagnostics Ltd’s price range in the past 12 months?
VentriPoint Diagnostics Ltd lowest stock price was C$0.08 and its highest was C$0.19 in the past 12 months.
What is VentriPoint Diagnostics Ltd’s market cap?
VentriPoint Diagnostics Ltd’s market cap is C$23.11M.
When is VentriPoint Diagnostics Ltd’s upcoming earnings report date?
VentriPoint Diagnostics Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 79 days.
How were VentriPoint Diagnostics Ltd’s earnings last quarter?
Currently, no data Available
Is VentriPoint Diagnostics Ltd overvalued?
According to Wall Street analysts VentriPoint Diagnostics Ltd’s price is currently Overvalued.
Does VentriPoint Diagnostics Ltd pay dividends?
VentriPoint Diagnostics Ltd does not currently pay dividends.
What is VentriPoint Diagnostics Ltd’s EPS estimate?
VentriPoint Diagnostics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VentriPoint Diagnostics Ltd have?
VentriPoint Diagnostics Ltd has 192,577,940 shares outstanding.
What happened to VentriPoint Diagnostics Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VentriPoint Diagnostics Ltd?
Currently, no hedge funds are holding shares in TSE:VPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VentriPoint Diagnostics Ltd
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---